GLIMDA-MV 1 Tablet SR

Description

GLIMDA-MV 1 Tablet is a triple combination antidiabetic medicine manufactured by Cipla Ltd. It contains Glimepiride (1mg), Metformin (500mg), and Voglibose (0.2mg), which work together to effectively control type 2 diabetes mellitus in adults.

• Glimepiride (1mg): A sulfonylurea that stimulates the pancreas to release insulin.

• Metformin (500mg): A biguanide that reduces glucose production in the liver and improves insulin sensitivity.

• Voglibose (0.2mg): An alpha-glucosidase inhibitor that slows down carbohydrate absorption from the intestine, preventing sudden spikes in blood sugar after meals.

This powerful combination targets different mechanisms of diabetes, offering better glycemic control compared to single-drug therapy.

Key Benefits:

• Provides comprehensive control of blood sugar levels in type 2 diabetes.

• Reduces fasting as well as post-meal blood sugar spikes.

• Helps lower the risk of diabetes-related complications like neuropathy, nephropathy, and retinopathy.

• Useful in patients who do not achieve sufficient control with single or dual therapy.

Usage & Dosage:

• Taken orally, usually once or twice daily with meals to avoid stomach upset.

• Dosage depends on individual blood sugar levels and doctor’s advice.

• Should be continued along with proper diet and exercise.

Safety Advice:

• Not suitable for type 1 diabetes or diabetic ketoacidosis.

• Risk of hypoglycemia may occur, especially if meals are skipped or excessive exercise is done.

• Should be avoided in patients with severe kidney or liver problems.

• Alcohol should be avoided, as it may increase the risk of lactic acidosis with metformin.

• Regular monitoring of blood sugar and HbA1c is recommended.

Possible Side Effects:

• Low blood sugar (sweating, hunger, dizziness)

• Stomach pain, bloating, diarrhea

• Nausea, metallic taste (due to metformin)

• Mild weight gain in some patients